Major US Drugmaker and Biotech Transactions Over the Past Decade
Overview of High-Profile Pharma and Biotech Deals
June 9 (Reuters) - GSK has agreed to buy cancer drug developer Nuvalent for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-term revenue growth.
The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity.
Below are some of the major deals involving U.S.-based pharma and biotech firms from the past decade
Major Transactions by Year
2026 Deals
GSK Acquires Nuvalent
Year Acquirer Target Deal Description
Value
2026 GSK Nuvalent $10.6 To expand
billion late-stage
cancer drug
pipeline
Boston Scientific Acquires Penumbra
2026 Boston Penumbra $14.5 To expand
Scientific billion vascular
pipeline
2025 Deals
Abbott Acquires Exact Sciences
2025 Abbott Exact up to $23 To gain
<ABT.N> Sciences billion access to
Exact
Sciences'
cancer tests,
including
flagship
colorectal
cancer test
Cologuard
Merck Acquires Cidara Therapeutics
2025 Merck Cidara $9.2 To gain
Therapeut billion access to
ics Cidara's
experimental
drug for flu
prevention
Pfizer Acquires Metsera
2025 Pfizer Metsera $10 To gain a
billion foothold in
the
fast-growing
obesity
treatment
market
Merck & Co Acquires Verona Pharma
2025 Merck & Verona About $10 Strengthens
Co Pharma billion Merck's
respiratory
portfolio
amid looming
Keytruda
patent cliff
Johnson & Johnson Acquires Intra-Cellular Therapies
2025 Johnson & Intra-Cel $14.6 Expands J&J's
Johnson lular billion footprint in
Therapies brain disease
treatments
2024 Deals
Novo Holdings Acquires Catalent
2024 Novo Catalent $16.5 Boosts
Holdings billion manufacturing
(includin capacity for
g debt), Novo
$11.5 Nordisk's
billion popular
(excludin obesity drug
g debt) Wegovy
2023 Deals
Merck & Co Acquires Prometheus Biosciences
2023 Merck & Prometheu $10.8 Adds
Co s billion experimental
Bioscienc treatment for
es ulcerative
colitis and
Crohn's
disease and
builds up
presence in
immunology
Bristol Myers Squibb Acquires Karuna Therapeutics
2023 Bristol Karuna $14 BMY gains a
Myers Therapeut billion promising
Squibb ics antipsychotic
medicine as
